1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Development of a sublingual allergy vaccine for grass pollinosis

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Grass pollen is a very common cause of allergic rhinitis and asthma. The only treatment targeting the underlying causes of allergy is immunotherapy (IT). Sublingual immunotherapy (SLIT) has been introduced to solve the problem of systemic reactions to subcutaneous IT (SCIT). This article evaluates the characteristics of the allergen extract, Staloral, in terms of practical administration, effectiveness, safety, and mechanism of action. Efficacy data were obtained from double-blind, placebo-controlled studies using Staloral in patients sensitized to grass pollen, while practical administration, cost-effectiveness, and mechanism of action data were provided by well designed studies. The efficacy and safety of Staloral, as demonstrated by review of published studies which used doses up to 1125 times those administered with SCIT, shows that this allergen extract has optimal characteristics for treating patients with seasonal allergies due to grass pollens. The main mechanism of action is the interaction between dendritic cells of the oral mucosa and the subsequent tolerance induced in T-cells.

          Related collections

          Author and article information

          Journal
          Drug Des Devel Ther
          Drug Design, Development and Therapy
          Dove Medical Press
          1177-8881
          2010
          21 July 2010
          : 4
          : 99-105
          Affiliations
          [1 ]Medical and Scientific Department, Stallergenes, Milan, Italy;
          [2 ]University Department of Medical and Surgical Specialties and Public Health, Perugia, Italy;
          [3 ]Laboratoire Stallergenes, Antony, France;
          [4 ]Marketing Department, Stallergenes, Milan, Italy;
          [5 ]Allergy/Pulmonary Rehabilitation Unit, ICP Hospital, Milan, Italy
          Author notes
          Correspondence: Cristoforo Incorvaia, Allergy/Pulmonary Rehabilitation Unit, ICP Hospital, via Bignami 1, Milan, Italy, Tel +39 025 799 3289, Fax +39 025 799 3315, Email cristoforo.incorvaia@ 123456gmail.com
          Article
          dddt-4-099
          2915534
          20689696
          © 2010 Frati et al, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          Categories
          Review

          Comments

          Comment on this article